Heron Therapeutics, Inc. , a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company's timeline for the resubmission of the new drug application for SustolA to the U.S. Food and Drug Administration , the Company's product candidate for chemotherapy-induced nausea and vomiting .
http://ift.tt/M4hM2e
http://ift.tt/M4hM2e
No comments:
Post a Comment